CRNX

Crinetics Pharmaceuticals Inc.宣布根据纳斯达克上市规则5635(C)(4)进行2025年9月诱导性授予。

时间：2025-09-11 04:31:23 市场：美股综合

关联： CRNX

Crinetics Pharmaceuticals Inc.获得FDA孤儿药资格认定，Atumelnant用于治疗先天性肾上腺增生症(CAH)

时间：2025-08-21 20:47:11 市场：美股综合

关联： CRNX

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

时间：2025-07-11 04:28:57 市场：综合美股

关联： CRNX

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

时间：2025-02-11 05:44:27 市场：美股综合

关联： CRNX

Crinetics Pharmaceuticals Shares Fall 7% to $48 After the Bell Following Stock Offering Announcement

时间：2024-10-09 04:08:03 市场：美股综合

关联： CRNX

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

时间：2024-10-09 04:01:51 市场：美股综合

关联： CRNX

Crinetics Pharmaceuticals- Proceeds to Fund R&D, Pre-Commercialization, and General Corporate Purposes

时间：2024-10-09 04:01:51 市场：美股综合

关联： CRNX

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

时间：2024-09-27 04:05:00 市场：综合美股

关联： CRNX

Crinetics Pharmaceuticals Inc - FDA Notification on Nda Status Expected in December

时间：2024-09-27 04:05:00 市场：美股综合

关联： CRNX

Crinetics Pharmaceuticals Inc - Phase 3 Studies Met All Primary and Secondary Endpoints

时间：2024-09-27 04:05:00 市场：综合美股

关联： CRNX